US based Novavax said its COVID-19 vaccine is more than 93% effective against the predominant transmissible varients.
The clinical trial studied nearly 30,000 volunteers in the U.S and Mexico, with the biotech company claiming side effects are minimal.
The protein-based vaccine is placed on fast track by the U.S government for late 2021 and could be a third vaccine option for Australia if approved by the Therapeutic Goods Administration.